Last reviewed · How we verify

Singulair — Competitive Intelligence Brief

Singulair (Singulair) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Respiratory.

marketed Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2 Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Singulair (Singulair) — Genuine Research Center, Egypt.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Singulair TARGET Singulair Genuine Research Center, Egypt marketed Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2
Singulair montelukast Merck & Co. marketed Leukotriene receptor antagonist (LTRA) Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2 1998-02-20

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Singulair — Competitive Intelligence Brief. https://druglandscape.com/ci/singulair. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: